To be continually recognised by our customers as the source of superior, cost‑effective, innovative solutions and technologies within infection prevention across all key critical areas of Hand & Skin asepsis, Hard Surface disinfection & Cleaning, Enzymatic instrument reprocessing, instrument disinfection and Environmental Hygiene.
WHAT WE DO
Novapharm Research has been recognised as a global leader in the skin asepsis category of infection control for over three decades. The company has an extensive patent portfolio and a series of platform technologies which have been recognised for their technological originality achieving functional advancements throughout the world. Novapharm’s expertise spans formulation, chemistry and microbiology together with dispensing and packaging.
Novapharm has powerful technology in hard surface disinfection and the pre-cleaning and re-processing of medical instruments, thus, an end-to-end infection control platform. Novapharm enjoys several accreditations including ISO13485.
Novapharm has developed a series of the world’s leading skin asepsis product ranges for our customers, including Microshield, Avagard and Asepti. We have also published multiple papers on microbial control and sat on numerous industry & technical committees.
Novapharm enjoys a broad Patent portfolio as well as a large portfolio of regulatory files and approvals in key global markets and has a strategic focus on work-flow and cost efficiency ‘in use’. There is an ongoing focus on new product pipelines together with a unique capability of adapting to customer technical needs across all business units so as to innovate and develop unique, broad IP based solutions that continue to “raise the bar” by delivering next generation / superior products.
WHAT WE OFFER
Side-by-side performance comparisons against competitors with respect to:
Cleaning efficacy on artificial and ISO 15883-5 challenge soils
Enzyme activity and storage stability analysis
Materials compatibility validations and testing
Biofilm removal efficacy
Full range of disinfection efficacy testing against common and emerging bacteria and viruses
Customised biocidal, cleaning and material compatibility validations
Support for worldwide tender documentation
Life cycle analysis of formulations and/or packaging
Our clients also benefit from Novapharm’s extensive collaboration with many institutions like:
University of NSW
University of Melbourne
Robert Koch Institute (RKI)
UK Health Protection Agency
CJD Surveillance Unit (UK)
THE TECHNOLOGY GROUP
Novapharm, through its senior board member connections with Aeris Environmental, Nanosonics and the Regional Health Care Group, have access to over 100 researchers, chemists, microbiologists and engineers with Novapharm and across Aeris, Nanosonics and the Regional Health Care Group.